MAZE
Maze Therapeutics·NASDAQ
--
--(--)
--
--(--)
8.05 / 10
Outperform
Analyst consensus is overwhelmingly bullish with a Strong Buy rating from one analyst and an 8.05 historical weighted score. Fund-flow dynamics are equally supportive, scoring 8.06/10 with positive trends across block, medium, large, and extra-large flows, though small flows show a slight negative bias. This confluence of positive analyst sentiment and capital inflow reinforces the stock's attractive profile.
Fund Flow Rating
Analyst RatingStrong Buy
Wall Street Opinions
Strong Buy
Strong Buy
100%
Buy
0%
Hold
0%
Sell
0%
Strong Sell
0%
Date2026-01-16
InstitutionBTIG
Times predicted4
Historical Win Rate100.0%
Is money flowing into or out of MAZE?
- MAZE holds a Bullish analyst rating, with 100% of experts assigning a Strong Buy grade. Factoring in net Inflows from order flow data, the comprehensive Sentiment Score stands at 8.05/10 (Outperform).
